Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

We speak to Novo Nordisk's Stephen Gough about the company’s drive to tackle complications of type 2 diabetes such as chronic kidney disease ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, through a new partnership with WeightWatchers starting ...

Some women may be unaware they’re living with risks for heart disease, kidney disease and metabolic conditions like diabetes, ...